MDxHealth (MDXH) to Release Quarterly Earnings on Thursday

MDxHealth (NASDAQ:MDXH) is expected to be announcing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $26.0540 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

MDxHealth Stock Down 1.7%

Shares of MDxHealth stock opened at $3.55 on Wednesday. MDxHealth has a 12-month low of $1.35 and a 12-month high of $5.33. The firm has a market capitalization of $175.73 million, a PE ratio of -5.55 and a beta of 1.64. The stock’s fifty day moving average is $3.53 and its 200-day moving average is $3.75.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Intesa Sanpaolo Wealth Management purchased a new stake in MDxHealth in the 4th quarter worth approximately $36,000. Lido Advisors LLC acquired a new position in shares of MDxHealth in the third quarter worth $48,000. Squarepoint Ops LLC purchased a new stake in shares of MDxHealth during the fourth quarter worth $51,000. Jefferies Financial Group Inc. acquired a new stake in MDxHealth during the third quarter valued at $53,000. Finally, Balyasny Asset Management L.P. acquired a new stake in MDxHealth during the fourth quarter valued at $68,000.

Wall Street Analysts Forecast Growth

A number of research firms have commented on MDXH. TD Cowen upped their price objective on shares of MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. Lake Street Capital upped their price target on shares of MDxHealth from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $7.00 price objective on shares of MDxHealth in a research note on Tuesday, December 23rd. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, MDxHealth currently has a consensus rating of “Moderate Buy” and an average price target of $7.75.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.